Thursday 7 May, 2026
Introduction: In vitro trimer formation modeling is commonly used to predict the dose at which pharmacological activity is observed for…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
AI AUTOMATION MEETS PBPK: AN R SHINY APPLICATION WITH LARGE LANGUAGE MODEL INTEGRATION FOR EFFICIENT PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL REPORTING
Thursday 7 May, 2026
Objectives: Physiologically based pharmacokinetic (PBPK) reporting often depends on manual collation of PK parameters across numerous simulation outputs and substantial…
Read morePhysiologically Based Pharmacokinetic Modeling to Evaluate Drug–Herbal Interactions Between Conventional GERD Therapies and Banhasasim-tang
Thursday 7 May, 2026
Objectives: Gastroesophageal reflux disease (GERD) is highly prevalent and frequently managed with both conventional pharmacotherapy and herbal formulations, highlighting the…
Read moreMODEL-BASED TESTING TO ASSESS CMAX BIOEQUIVALENCE IN HIGHLY VARIABLE DRUGS
Thursday 7 May, 2026
Introduction: In bioequivalence trials, regulatory authorities recommend testing average bioequivalence (ABE) between a test (T) and a reference (R) product…
Read moreA semi-mechanistic model for tumor regression effects of IL-2 receptor-targeted nanocarrires modulating Treg activity
Thursday 7 May, 2026
Objectives Targeting regulatory T cells (Tregs) is a promising approach to overcome tumor-driven immunosuppression. For this purpose, P60 peptide shows…
Read moreFinite Pharmacokinetics (FTPK) Software: A Giant Step Toward Model-Informed Drug and Generics Development (MIDGD)
Thursday 7 May, 2026
Introduction Pharmacokinetic (PK) analyses, data evaluation, and simulations assume that absorption of drugs administered orally or otherwise lasts forever since…
Read moreA physiologically-based pharmacokinetic model for intraperitoneal irinotecan to evaluate the impact of UGT1A1 variability on SN-38 exposure
Thursday 7 May, 2026
Objectives Intraperitoneal (IP) irinotecan is currently being investigated for treatment of peritoneal metastases, to overcome limited IP drug availability associated…
Read moreIN VITRO-IN VIVO EXTRAPOLATION OF ACTIVE INFLUX BY THE PROTON-COUPLED ANTIPORTER FOR PBPK PREDICTIONS OF CNS PHARMACOKINETICS IN EARLY DRUG DISCOVERY: A CASE STUDY ON OXYCODONE
Thursday 7 May, 2026
Objectives: Poor understanding of central nervous system (CNS) target site pharmacokinetics (PK) is a major contributor to high attrition rates…
Read moreA simple algebraic expression can determine if a drug’s clearance is non-specific or target-mediated
Thursday 7 May, 2026
Target-mediated drug distribution (TMDD) is typically classified by accelerated removal of drug after serum concentration drops below a critical level…
Read moreIntegrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies
Thursday 7 May, 2026
Objective Monoclonal antibodies (mAbs) frequently exert their pharmacological effects by competing with endogenous ligands for binding to shared targets, thereby…
Read more